[[(E)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [[(E)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium
• 化学式: C10H17N4O3+
• 分子量: 241.27
• InChiKey: WWGJEDDFWJBVPW-XYOKQWHBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  77.9
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] CONJUGATES OF TACROLIMUS, THEIR COMPOSITIONS, AND THEIR USES<br/>[FR] CONJUGUÉS DE TACROLIMUS, LEURS COMPOSITIONS ET LEURS UTILISATIONS
  申请人：THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

  公开号：WO2017165607A1

  公开（公告）日：2017-09-28

  Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) including but not limited to conjugates comprising FK-506 and ascomycin. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating. Further embodiments include methods for making the inventive compound. Additional embodiments of the invention are also discussed herein.

  本发明的某些实施例包括创新化合物（例如，公式（I）的化合物），包括但不限于包含FK-506和ascomycin的缀合物。其他实施例包括由创新化合物组成的组合物（例如，药物组合物）。本发明的进一步实施例包括用于治疗某些疾病的组合物，例如，使用创新化合物。一些实施例包括使用创新化合物的方法（例如，在组合物中或药物组合物中）用于给药和治疗。进一步的实施例包括制造创新化合物的方法。本发明还讨论了其他的实施例。
• [EN] AMINO-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS DE L'ACIDE 3-HÉTÉROAROYLAMINO-PROPIONIQUE AMINO SUBSTITUÉS ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2012101199A1

  公开（公告）日：2012-08-02

  Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals The present invention relates to compounds of the formula (I), wherein A, D, E, G, R10 R11, R30 R40 R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  氨基取代的3-杂环酰胺基丙酸衍生物及其作为药物的用途。本发明涉及式(I)的化合物，其中A、D、E、G、R10、R11、R30、R40、R50和R60具有权利要求中所示的含义，它们是有价值的药用活性化合物。它们是蛋白酶卡特普西A的抑制剂，可用于治疗动脉粥样硬化、心力衰竭、肾脏疾病、肝脏疾病或炎症性疾病等疾病。此外，本发明还涉及制备式I化合物的方法、它们的用途以及包含它们的药物组合物。
• [EN] PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R, 2S, 5S)-3-AZABICYCLO[3, 1, 0]HEXANE-2-CARBOXAMIDE, N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2, 3-DIOXOPROPYL] ]-3-[(2S)-2-[[[1, 1-DIMETHYLETHYL]AMINO]CARBONYLAMINO]-3, 3-DIMETHYL-1-OXOBUTYL]-6, 6-DIMETHYL<br/>[FR] PROCEDE ET INTERMEDIAIRES POUR PREPARER DU (1R,2S,5S)-3-AZABICYCLO[3,1,0]HEXANE-2-CARBOXAMIDE, N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL]-3-[(2S)-2-[[[1,1-DIMETHYLETHYL]AMINO]CARBONYLAMINO]-3,3-DIMETHYL-1-OXOBUTYL]-6,6-DIMETHYLE
  申请人：SCHERING CORP

  公开号：WO2004113294A1

  公开（公告）日：2004-12-29

  In one embodiment, the present application relates to a process of making a compound of formula (I): and to certain intermediate compounds that are made within the process of making the compound of formula (I).

  在一个实施例中，本申请涉及制备化合物(I)的过程，以及在制备化合物(I)过程中制备的某些中间化合物。
• Beta-aminoacid-derivatives as factor Xa inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1571154A1

  公开（公告）日：2005-09-07

  The present invention relates to compounds of the formula I, in which R0 ; R1 ; R2 ; R3 ; R4; R5, R6, Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R0; R1; R2; R3; R4; R5，R6，Q; V，G和M具有索赔中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血凝酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于存在因子Xa和/或因子VIIa的不良活性或对其进行抑制的治疗或预防的情况。此外，本发明涉及式I化合物的制备方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。
• Benzimidazole-derivatives as factor xa inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1479676A1

  公开（公告）日：2004-11-24

  Benzimidazole-derivatives as factor Xa inhibitors The present invention relates to compounds of the formula I, wherein R0 ; R1 ; R2 ; R3 ; R4; Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  苯并咪唑衍生物作为因子Xa抑制剂本发明涉及以下式I的化合物，其中R0; R1; R2; R3; R4; Q; V，G和M具有所述声明中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血液凝固酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于存在因子Xa和/或因子VIIa不良活性的情况，或者用于治疗或预防需要抑制因子Xa和/或因子VIIa的情况。此外，本发明还涉及式I化合物的制备方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制剂。